Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Lantern Pharma Inc Registered Shs Stock , LTRN

4.75 0.00 0.00%
Official Close 3/17/2023 NAS
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 03/17/2023 the closing price of the Lantern Pharma Inc Registered Shs share was $4.75 on NAS. Compared to the opening price on Friday 03/17/2023 on NAS of $4.80, this is a drop of 1.05%. Lantern Pharma Inc Registered Shs's market capitalization is $50.29 M by 10.86 M shares outstanding.
Is Lantern Pharma stock a Buy, Sell or Hold? Lantern Pharma stock has received a consensus rating of buy. The average rating score is and is based on 3 buy ratings, 0 hold ratings, and 0 sell ratings.
What was the 52-week low for Lantern Pharma stock? The low in the last 52 weeks of Lantern Pharma stock was 4.10. According to the current price, Lantern Pharma is 115.85% away from the 52-week low.
What was the 52-week high for Lantern Pharma stock? The high in the last 52 weeks of Lantern Pharma stock was 7.92. According to the current price, Lantern Pharma is 59.97% away from the 52-week high.
What are analysts forecasts for Lantern Pharma stock? The 3 analysts offering price forecasts for Lantern Pharma have a median target of 34.00, with a high estimate of 36.00 and a low estimate of 32.00. The median estimate represents a 13.97 difference from the last price of 4.75.

Lantern Pharma Stock Snapshot

4.69
Bid
200.00
Bid Size
4.75
Ask
300.00
Ask Size
3/17/2023
Date
8:00 PM
Time
14,178.00
Volume
4.92
Prev. Close
4.80
Open
50.29 M
Market Cap
10.86 M
Number of Shares
4.63
Day Low
4.80
Day High
4.75
4.10
52 Week Low
7.92
52 Week High
4.75
62.77
Free Float in %
-1.88
EPS 2023

Lantern Pharma Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Lantern Pharma Analyst Data

Total Analysts: 3
Buy Ratings: 3 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 32.00 Median: 34.00 Highest: 36.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Lantern Pharma Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
03/11/22 H.C. Wainwright & Co.
Maintained Buy $36
11/02/21 H.C. Wainwright & Co.
Maintained Buy $34
10/07/21 H.C. Wainwright & Co.
Maintained Buy $32

Lantern Pharma Estimates* in USD

  2023 2024 2025 2026
Revenue 0 0 0 0
Dividend - - - -
Dividend Yield (in %) - - - -
EPS -1.88 -2.14 -1.76 -1.62
P/E Ratio -2.53 -2.22 -2.70 -2.93
EBIT -21 -29 -47 -58
EBITDA -22 -32 -45 -56
Net Profit -21 -29 -46 -57
Net Profit Adjusted -21 - - -
Pre-Tax Profit -22 -30 -46 -57
Net Profit (Adjusted) - - - -
EPS (Non-GAAP) ex. SOE - - - -
EPS (GAAP) -1.93 -2.42 - -
Gross Income 0 0 0 0
Cash Flow from Investing 0 0 0 0
Cash Flow from Operations -22 -31 -44 -54
Cash Flow from Financing 0 100 100 100
Cash Flow per Share - - - -
Free Cash Flow - - - -
Free Cash Flow per Share - - - -
Book Value per Share - - - -
Net Debt - - - -
Research & Development Exp. 15 23 33 41
Capital Expenditure 0 0 0 0
Selling, General & Admin. Exp. 8 9 10 13
Shareholder’s Equity 30 99 155 201
Total Assets 35 104 160 206
  Previous Quarter Current Quarter Next Quarter Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts - 1 - 3 2
Average Estimate - -0.480 USD - -1.877 USD -2.140 USD
Year Ago - -0.380 USD - - -1.877 USD
Publish Date - 5/2/2023 - - -
Revenue Estimates
No. of Analysts - - - 2 1
Average Estimate - - - 0 USD 0 USD
Year Ago - - - - 0 USD
Publish Date - - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Lantern Pharma Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Kreis Leslie W. 11/07/2022 40,586.00 164,137.00 4.40 Sell No
Kreis Leslie W. 11/07/2022 132,575.00 536,163.00 4.40 Sell No
Kreis Leslie W. 11/07/2022 17,748.00 71,774.00 4.40 Sell No
Kreis Leslie W. 11/07/2022 100,380.00 463,658.00 4.40 Sell No
Kreis Leslie W. 11/07/2022 58,711.00 271,193.00 4.40 Sell No
Kreis Leslie W. 11/07/2022 40,586.00 164,137.00 4.40 Sell No
Kreis Leslie W. 11/07/2022 132,575.00 536,163.00 4.40 Sell No
Kreis Leslie W. 11/07/2022 17,748.00 71,774.00 4.40 Sell No
Kreis Leslie W. 11/07/2022 100,380.00 463,658.00 4.40 Sell No
Kreis Leslie W. 11/07/2022 58,711.00 271,193.00 4.40 Sell No
Kreis Leslie W. 09/01/2022 1,275.00 26,093.00 5.20 Sell No
Kreis Leslie W. 09/01/2022 5,170.00 20,930.00 5.20 Sell No
Kreis Leslie W. 09/01/2022 1,275.00 26,093.00 5.20 Sell No
Kreis Leslie W. 09/01/2022 5,170.00 20,930.00 5.20 Sell No
Kreis Leslie W. 09/01/2022 6,438.00 27,328.00 1.03 Buy No
Kreis Leslie W. 09/01/2022 26,100.00 26,100.00 1.03 Buy No
Kreis Leslie W. 09/01/2022 6,438.00 27,328.00 1.03 Buy No
Kreis Leslie W. 09/01/2022 26,100.00 26,100.00 1.03 Buy No
Kreis Leslie W. 03/16/2022 35,347.00 329,904.00 110,636.11 Buy No
Kreis Leslie W. 03/16/2022 60,432.00 564,038.00 189,152.16 Buy No
KEYSER D JEFFREY 06/14/2020 31,927.00 41,927.00 n/a Buy No
Green Park & Golf Ventures II, LLC 06/14/2020 131,697.00 131,697.00 n/a Buy No
Green Park & Golf Ventures II, LLC 06/14/2020 292,605.00 292,605.00 n/a Buy No
Green Park & Golf Ventures II, LLC 06/14/2020 41,535.00 211,291.00 n/a Buy No
Kreis Leslie W. 06/14/2020 61,214.00 89,522.00 n/a Buy No

Lantern Pharma Dividend Calendar

Date Name Dividend *yield Currency
2021 Lantern Pharma Inc Registered Shs - - USD
2020 Lantern Pharma Inc Registered Shs - - USD
2019 Lantern Pharma Inc Registered Shs - - USD
2018 Lantern Pharma Inc Registered Shs - - USD
*Yield of the Respective Date

Lantern Pharma Inc Registered Shs Calendar

Event Estimate Info Date
Earnings Report - Q4 2022 Earnings Release 03/20/2023
Earnings Report -0.480 USD Q1 2023 Earnings Release 05/02/2023
Earnings Report - Q2 2023 Earnings Release 08/03/2023
Earnings Report - Q3 2023 Earnings Release 11/01/2023
Earnings Report - Q4 2023 Earnings Release 03/07/2024

Lantern Pharma Profile

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX. .

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
5
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Lantern Pharma Shareholder

Owner in %
Freefloat 62.77
BIOS Capital Management LP 14.12
David S. Silberstein, PhD 8.83
ProPhase Labs, Inc. 8.38
Corriente Advisors LLC 5.76
Green Park & Golf Ventures LLC 5.51
Pinnacle Summer Investments, Inc. 3.37
Vanguard Group, Inc. (Subfiler) 3.36
Vanguard Total Stock Market Index Fund 2.36
NewEdge Advisors LLC 1.59
Flagship Harbor Advisors LLC 1.36
Carlson Capital LP 1.27
Vanguard Extended Market Index Fund 0.91
Anson Funds Management LP 0.60
CM Management LLC 0.55
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.